For the year ending 2025-12-31, SREA had $1,963M increase in cash & cash equivalents over the period. -$6,047M in free cash flow.
| Cash Flow | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Income from continuing operations, net of income tax | - | - | - | 2,285 |
| Net income | 2,072 | 3,500 | 3,618 | - |
| Regulatory disallowances | 651 | - | - | - |
| Depreciation and amortization | 2,563 | 2,437 | 2,227 | 2,019 |
| Deferred income taxes and investment tax credits | 533 | -20 | 249 | 392 |
| Gain on sale of assets | - | - | 1 | 0 |
| Equity earnings | 1,604 | 1,609 | 1,481 | 1,498 |
| Foreign currency transaction (gains) losses, net | - | - | 2 | -24 |
| Share-based compensation expense | 64 | 86 | 80 | 71 |
| Fixed-price contracts and other derivatives | -92 | 197 | 666 | -863 |
| Bad debt expense | 65 | 209 | 458 | - |
| Other | 16 | -20 | 11 | -154 |
| Accounts receivable | 66 | -118 | -168 | 976 |
| Due to/from unconsolidated affiliates, net | -17 | -30 | -26 | 31 |
| Income taxes receivable/payable, net | -187 | -49 | 142 | -29 |
| Inventories | 64 | 74 | 80 | 17 |
| Other current assets | 296 | 30 | -11 | 1,608 |
| Accounts payable | -7 | -131 | -270 | 430 |
| Regulatory balancing accounts, net | 829 | 456 | -260 | -36 |
| Reserve for aliso canyon costs | - | -12 | -98 | -1,851 |
| Other current liabilities | 177 | 142 | 1,270 | 228 |
| Insurance receivable for aliso canyon costs | - | 0 | 0 | -360 |
| Distributions from investments | 1,120 | 1,093 | 912 | 854 |
| Reserve for aliso canyon costs, noncurrent | - | - | - | 1 |
| Changes in other noncurrent assets and liabilities, net | -280 | 150 | 594 | 565 |
| Net cash provided by continuing operations | - | - | - | 1,142 |
| Net cash used in discontinued operations | - | - | - | 0 |
| Net cash provided by operating activities | 4,565 | 4,907 | 6,218 | 1,142 |
| Expenditures for property, plant and equipment | 10,612 | 8,215 | 8,397 | 5,357 |
| Expenditures for investments | 2,015 | 988 | 382 | 376 |
| Proceeds from sale of assets | - | - | 3 | 0 |
| Return on investments | 0 | 9 | 0 | - |
| Purchases of nuclear decommissioning and other trust assets | 1,031 | 889 | 610 | 700 |
| Proceeds from sales of nuclear decommissioning and other trust assets | 1,098 | 942 | 661 | 762 |
| Advances to unconsolidated affiliates | - | - | 0 | 0 |
| Repayments of advances to unconsolidated affiliates | - | 0 | 0 | 626 |
| Disbursement for note receivable | - | - | 0 | 0 |
| Other | -23 | -23 | -9 | -6 |
| Net cash used in continuing operations | - | - | - | -5,039 |
| Net cash provided by discontinued operations | - | - | - | 0 |
| Net cash used in investing activities | -12,537 | -9,118 | -8,716 | -5,039 |
| Common dividends paid | 1,603 | 1,499 | 1,483 | 1,430 |
| Preferred dividends paid | 40 | 44 | 44 | 44 |
| Issuances of preferred stock, net | - | - | - | 0 |
| Redemption of preferred stock | 900 | - | - | - |
| Issuances of common stock, net | 32 | 1,219 | 145 | 4 |
| Repurchases of common stock | 58 | 43 | 32 | 478 |
| Issuances of debt (maturities greater than 90 days) | 11,282 | 8,674 | 7,669 | 9,984 |
| Payments on debt (maturities greater than 90 days) and finance leases | 5,220 | 3,339 | 6,294 | 4,510 |
| Increase (decrease) in short-term debt, net | 1,262 | -557 | 552 | -1,266 |
| Advances from unconsolidated affiliates | 150 | 85 | 31 | 28 |
| Contributions from contingently redeemable noncontrolling interest, net of transaction costs | 5,294 | - | - | - |
| Proceeds from investor equity subscription | 106 | - | - | - |
| Proceeds from sales of noncontrolling interests, net | 0 | 0 | - | - |
| Contributions from noncontrolling interests | 327 | 1,235 | 1,219 | 1,732 |
| Purchases of noncontrolling interests | - | - | 0 | 0 |
| Distributions to noncontrolling interests | 609 | 297 | 730 | -237 |
| Contributions from noncontrolling interests | - | - | 1,570 | 31 |
| Settlement of cross-currency swaps | - | - | 99 | - |
| Termination of interest rate and settlement of cross-currency swaps | 0 | -46 | - | - |
| Other | -93 | -56 | -85 | -35 |
| Net cash provided by (used in) continuing operations | - | - | - | 3,779 |
| Net cash provided by discontinued operations | - | - | - | 0 |
| Net cash (used in) provided by financing activities | 9,930 | 5,424 | 2,419 | 3,779 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | - | -13 | 6 | -1 |
| Effect of exchange rate changes in discontinued operations | - | - | - | 0 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 5 | - | - | -1 |
| (decrease) increase in cash, cash equivalents and restricted cash | 1,963 | 1,200 | -73 | -119 |
| Cash, cash equivalents and restricted cash, january 1 | 1,589 | 389 | - | 581 |
| Cash, cash equivalents and restricted cash, december 31 | 3,552 | 1,589 | - | 462 |
SEMPRA (SREA)
SEMPRA (SREA)